Florida Expo organizers said more than 7,000 people signed up for the free event, which became a sort of one-stop shop for those seeking job opportunities, better quality of life and recommendations for the best neighborhoods and schools.
Dozens waited in line for more than an hour to submit their personal information and receive job leads and other data. Some criticized Puerto Rico's government for not doing enough to improve the lives of working-class families.
"There's more opportunities if you move," said Elsie Melendez, a 37-year-old mother of two who lives in the northern town of Vega Baja. "People who live off government support here are doing better than those of us who work and pay taxes."
Top 10 Long Term Companies To Watch In Right Now: Mears Group PLC (MER)
Mears Group PLC (Mears Group) is a holding company. The principal activities of the Company are the provision of a range of outsourced services to the public and private sectors. The Company operated in three business segments: social housing, which provides a full repair and maintenance service to local authorities and other registered social housing landlords in the United Kingdom; domiciliary care, which provides personal care services to people in their own homes and mechanical and electrical (M&E), which consists of provision of design and build M&E services. The Company�� subsidiaries include Mears Limited, Haydon Mechanical & Electrical Limited, Scion Technical Services Limited, Scion Estates Limited, Jackson Lloyd Limited, Morrison Facilities Services Limited, Morrison Facilities Services Limited, Manchester Working Limited and Mears Home Improvements Limited. Effective August 13, 2013, Mears Group PLC acquired a 50% interest in Just Call 24/7 (UK) Ltd. Advisors' Opinion:- [By John Heinzl]
If you're uncomfortable picking individual preferred shares, a diversified exchange-traded fund, such as CPD can be a good option. The fund, which has about $1.4-billion under management, holds more than 200 preferred shares, with banks and insurance companies accounting for more than half of the assets. The fund has a management expense ratio (MER) of 0.5%.
Top 10 Quality Companies To Buy Right Now: Hercules Offshore Inc.(HERO)
Hercules Offshore, Inc., together with its subsidiaries, provides shallow-water drilling and marine services to the oil and natural gas exploration and production industry in the U.S. Gulf of Mexico and internationally. Its services comprise oil and gas exploration and development drilling, well services, platform inspection, and maintenance and decommissioning services in various water provinces. As of May 10, 2011, the company owned and operated a fleet of 50 jackup rigs, 17 barge rigs, 65 liftboats, 3 submersible rigs, and 1 platform rig. It serves national oil and gas companies, integrated energy companies, and independent oil and natural gas operators. The company was founded in 2004 and is headquartered in Houston, Texas.
Advisors' Opinion:- [By Dimitra DeFotis]
The market seems to be showing fatigue particularly with positive onshore oil service data points that may no�longer seem incremental. Investors have become especially focused on potential issues and macro concerns. We believe this phase�of enhanced risk perceptions will pass and still recommend owning selective stocks based on attractive valuations and healthy�fundamentals. Of the 16 oilfield services companies having reported their quarters to date, the share price changes have at times�been difficult to tie to specific results. �… Five of the 12 companies who have beaten earnings expectations have seen their share prices drop on the day, including Basic Energy Services (BAS) (-9.0%), Baker Hughes (BHI) (-2.5%), National Oilwell Varco (NOV) (-1.5%), Oceaneering (OII) (-4.2%), and Schlumberger (SLB) (-2.0%). Other stocks beating expectations have traded higher as expected, including Cameron International (CAM) (+4.1%), FMC Technologies (FTI) (+3.1%), Mitcham Industries (MIND) (+3.8%), Nabors Industries (NBR) (+1.2%), Patterson-UTI Energy (PTEN) (+1.8%), RPC (RES) (+8.4%), and Weatherford International (WFT) (+2.3%). Companies which have missed have universally seen their share prices decline, including Diamond Offshore Drilling (DO) (-4.3%), Gulfmark Offshore (GLF) (-0.1%), and Hercules Offshore (HERO) (-6.9%). Halliburton (HAL) was in line and flat on the day.
- [By Travis Hoium]
Hercules Offshore (NASDAQ: HERO ) is one of only a few companies left that focuses on shallow water drilling. But even now it's moving away from onshore shallow water by selling rigs that have little use to the company. This is a good move right now but does it make Hercules a top drilling stock? Fool.com contributor Travis Hoium took a look at Hercules' recent $45 million asset sale and discovered that there are still better drilling buys out there.�
Top 10 Quality Companies To Buy Right Now: Potomac Electric Power Company(POM)
Pepco Holdings, Inc., through its subsidiaries, engages in the transmission, distribution, and supply of electricity. The company also distributes and supplies natural gas. It distributes electricity to approximately 1.8 million customers in the mid-Atlantic region and delivers natural gas to approximately 123,000 customers in Delaware. In addition, the company involves in the retail supply of electricity and natural gas; provision of energy efficiency services to federal, state, and local government customers; and designs, constructs, and operates combined heat and power and central energy plants, as well as owns and operates two oil-fired generation facilities. Further, it offers high voltage electric construction and maintenance services, low voltage electric construction and maintenance services, and streetlight construction and asset management services to utilities, municipalities, and other customers in the Washington, District of Columbia. Additionally, the company holds investments in eight cross-border energy leases. Pepco Holdings, Inc. was founded in 1896 and is based in Washington, District of Columbia.
Advisors' Opinion:- [By Jake L'Ecuyer]
Top Headline
Pepco Holdings (NYSE: POM) reported a 35% rise in its fourth-quarter profit. For the year, Pepco projects earnings of $1.12 to $1.27 per share, versus analysts' estimates of $1.22 per share. Pepco's quarterly earnings surged to $58 million, or $0.23 per share, versus a year-ago profit of $43 million, or $0.18 per share. Excluding one ��ime items, its earnings from continuing operations came in at $0.24 per share. Its total operating revenue climbed 3.3% to $1.09 billion. However, analysts were expecting earnings of $0.21 per share on revenue of $1.11 billion. - [By Ben Levisohn]
Pepco (POM) has surged 18% to $26.87 after it agreed to be purchased by Exelon (EXC) for $27.25 a share in an all-cash deal. Exelon has dropped 2.4% to $35.31.
- [By Ben Levisohn]
Visa (V) gained 2.8% this week and Walt Disney (DIS) rose 2.7% to $80.31, to lead the Dow higher. Visa managed to gain despite sanctions being imposed on two Russian banks. Pepco Holdings (POM) surged 24% after it agreed to be purchased by Exelon (EXC) for $27.25 a share in an all-cash deal. Exelon dropped 1.2% this week. Energizer (ENR) jumped 17% after it said it would split itself into two companies.
- [By Ben Levisohn]
Exelon�shares have been no doubt strong year-to-date, but we think the improvement in underlying business fundamentals is far from reflected in the share price, particularly after the pullback around equity to fund Pepco (POM).
Top 10 Quality Companies To Buy Right Now: Galena Biopharma Inc (GALE)
Galena Biopharma, Inc. (Galena), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVaxTM (E75), for the treatment of breast cancer and other tumors. NeuVax is a peptide-based immunotherapy intended to reduce the recurrence of breast cancer in low-to-intermediate HER2-positive breast cancer patients not eligible for trastuzumab (Herceptin; Genentech/Roche). On January 19, 2012, the Company initiated enrollment in its Phase 3 PRESENT clinical trial for NeuVax (E75 peptide plus GM-CSF) vaccine in low-to-intermediate HER2 1+ and 2+ breast cancer patients in the adjuvant setting to prevent recurrence (Clinicaltrials.gov identifier NCT01479244). The Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment study is a randomized, multicenter, multinational clinical trial that will enroll approximately 700 breast cancer patients. The Company�� Phase 2 trial of NeuVax achieved its primary endpoint of disease-free survival (DFS). On April 13, 2011, the Company completed its acquisition of Apthera, Inc.,(Apthera).
The Company focuses to start a Phase 2 trial comparing NeuVax in combination with trastuzumab (Herceptin) versus trastuzumab, alone, in a 300-patient, randomized study in the adjuvant breast cancer setting. The Company's second product candidate, Folate Binding Protein-E39 (FBP), is a vaccine, consisting of the peptides E39 and J65, aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. On February 14, 2012, the Company announced the initiation of a Phase 1/2 clinical trial in two gynecological cancers: ovarian and endometrial adenocarcinomas. Folate binding protein has ! very limited tissue distribution and expression in non-malignant tissue and is over-expressed in more than 90% of ovarian and endometrial cancers, as well as in 20% to 50% of breast, lung, colorectal and renal cell carcinomas.
In April 2011, the Company acquired Apthera Inc and its NeuVax product candidate. The Company focuses on developing a pipeline of immunotherapy product candidates for the treatment of various cancers based on the E75 peptide, the advanced of which is NeuVax, which is targeted at preventing the recurrence of breast cancer. NeuVax has had positive Phase 1/2 clinical trial results for the prevention of breast cancer recurrence in patients who have had breast cancer and received the standard of care treatment (surgery, chemotherapy, radiotherapy and hormonal therapy as indicated). The Company had also initiated its Phase 3 PRESENT clinical trial of NeuVax for the prevention of breast cancer recurrence in early-stage low-to-intermediate HER2 breast cancer patients. NeuVax directs killer T-cells to target and destroy cancer cells that express HER2/neu, a protein associated with epithelial tumors in breast, ovarian, pancreatic, colon, bladder and prostate cancers. NeuVax is comprised of a HER2/neu-derived peptide called E75. E75 is a nine-amino acid sequence that is immunogenic (produces an immune response) and GM-CSF is a commercially available protein that acts to stimulate and activate components of the immune system such as macrophages and dendritic cells.
The Company also develops novel applications for NeuVax based on preclinical studies and phases 2 clinical trials which suggest that combining NeuVax and trastuzumab (Herceptin; Genentech/Roche) can increase antigen presentation by tumor cells by promoting receptor internalization and subsequent proteosomal degradation of the HER2 protein. The Company also is pursuing additional therapeutic indications for NeuVax that are in Phase 1/2 clinical trials. RXI-109, is a dermal anti-scarring therapy that targets! connecti! ve tissue growth factor (CTGF) and that may inhibit connective tissue formation in human fibrotic disease.
The Company competes with Roche Laboratories, Inc., Pfizer Inc., Bayer HealthCare AG, Sanofi-Aventis, US, LLC, Amgen, Inc., GlaxoSmithKline plc, Renovo Group plc, CoDa Therapeutics, Inc., Sirnaomics, Inc., FirstString Research, Inc., Merz Pharmaceuticals, LLC, Capstone Therapeutics, Halscion, Inc., Garnet Bio Therapeutics, Inc., AkPharma Inc., Promedior, Inc., Kissei Pharmaceutical Co., Ltd., Eyegene, Derma Sciences, Inc., Healthpoint Biotherapeutics, Pharmaxon, Excaliard Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Marina Biotech, Inc., Tacere Therapeutics, Inc., Benitec Limited, OPKO Health, Inc., Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Rosetta Genomics Ltd., Lorus Therapeutics, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Regulus Therapeutics Inc. and Santaris.
Advisors' Opinion:- [By Sean Williams]
The waiting game
The tables are clearly stacked against small biotech companies developing cancer drugs. History has shown that few (if any) have successfully had the Food and Drug Administration approve a late-stage cancer drug. While mid-stage trials of Galena Biopharma's (NASDAQ: GALE ) HER2-targeting breast cancer vaccine have been promising thus far, the chances of an approval seem a long way off.
Top 10 Quality Companies To Buy Right Now: Alston Energy Inc (ALO)
Alston Energy Inc. (Alston) is a Canada-based petroleum and natural gas company. The Company is engaged in the exploration and production of oil and natural gas reserves in Western Canada�� sedimentary basins. The Company�� projects include Alexander, Pembina and Chauvin. Alexander assets include a 14.0% average working interest in 10 proved producing gas/oil wells, three proved development locations, related production facilities and pipelines and 6,560 gross acres of mineral leases. Pembina assets include a 3.5% interest in 19 producing oil wells, one coal bed methane gas well, four standing or suspended wells, two oil batteries, related production facilities and pipelines and 5,690 gross acres of land in the Pembina/Cardium Pool. Alston has oil assets in the emerging Chauvin area resource play. Advisors' Opinion:- [By victorselva]
Furthermore, yesterday we found on the news that General Electric will buy Alstom SA (ALO), the French builder of power plants and transmission gear. The deal could consist on the separation of Alstom�� transport business, which manufactures high-speed TGV trains, to make easier the approval of the French government. A potential value for Alstom at about $13 billion would be about 25 percent more than its current market value. As a consequence, stock price surged as much as 18 percent in Paris, the biggest jump in the last nine years. General Electric will gain control of Alstom�� technology for power transmission and power plant maintenance.
- [By Sarah Jones]
HSBC, Europe�� biggest bank, Societe Generale SA (GLE), France�� second-largest lender, and Germany�� Commerzbank AG each climbed at least 2.6 percent after posting results. Allianz gained 3.6 percent after Europe�� largest insurer reported a jump in profit. Alstom SA (ALO) sank 12 percent after the power-equipment maker cut its profit forecast.
Top 10 Quality Companies To Buy Right Now: iShares 1-3 Year Treasury Bond ETF (SHY)
iShares Lehman 1-3 Year Treasury Bond Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the short-term sector of the United States Treasury market as defined by the Lehman Brothers 1-3 Year U.S. Treasury Index (the Index). The Index includes all publicly issued United States Treasury securities that have a remaining maturity of between 1 and 3 years, are non-convertible, are denominated in United States dollars, are rated investment grade (Baa3 or better) by Moody�� Investors Service, are fixed rate, and have $250 million or more of outstanding face value. Excluded from the Index are certain special issues, such as flower bonds, targeted investor notes (TINs), and state and local government bonds (SLGs), and coupon issues that have been stripped from assets already included in the Index.
The Index is a market capitalization-weighted index. The Fund invests in a representative sample of the securities in the Index, which has a similar investment profile as the Index. The Fund�� investment advisor is Barclays Global Fund Advisor.
Advisors' Opinion:- [By Donald van Deventer]
Shorter-duration Treasury Exchange-Traded Funds: (SHY), (SHV), (IEI), (BIL), (TUZ), (FIVZ), (DTUL), (VGSH), (DTUS), (DFVS), (DFVL), (SST), (ISTB), (TBZ).
Top 10 Quality Companies To Buy Right Now: Select Sector Utilities Select Sector SPDR Fund (XLU)
Select Sector Utilities Select Sector SPDR Fund (the Fund), formerly Utilities Select Sector SPDR Fund, seeks to provide investment results that correspond to the price and yield performance of the Utilities Select Sector of the S&P 500 Index (the Index). The Index includes companies that produce, generate, transmit or distribute electricity or natural gas.
The Fund utilizes a passive or indexing investment approach to invest in a portfolio of stocks that seek to replicate the Index. The Fund�� investment advisor is SSgA Funds Management, Inc.
Advisors' Opinion:- [By Markos Kaminis]
Capital flows into equity funds have mostly found safe bets this year, with consumer staples, utilities and healthcare shares doing well. You can see this in the charts of the Utilities Select Sector SPDR (XLU), Consumer Staples Select Sector SPDR (XLP) and the Health Care Select Sector SPDR (XLV).
- [By Rich Bieglmeier]
To compare relative strength and to execute trades, Bilello and �Gayed use Utilities SPDR (ETF)(NYSEARCA:XLU) �and the Vanguard Total Stock Market ETF (NYSEARCA:VTI).
No comments:
Post a Comment